Diclofenac Potassium vs Articaine for Pain Management in Mandibular Molars with Irreversible Pulpitis
This study aims to compare the effectiveness of Diclofenac Potassium and Articaine in managing pain for adults with irreversible pulpitis in their lower back teeth.
Diclofenac Potassium
Treatment Study
Summary
Study start date: August 1, 2024
Actual date on which the first participant was enrolled.This study is examining how two different medications, Diclofenac Potassium and Articaine 4%, work when injected directly into the ligament around a tooth to provide pain relief. The focus is on patients who have symptomatic irreversible pulpitis, a painful condition affecting the nerves inside molar teeth, specifically in the lower jaw. This research is important because it aims to find out which medication offers better pain relief during and after a root canal treatment, potentially improving comfort and outcomes for patients with this dental issue. Participants in the study receive an injection of either Diclofenac Potassium or Articaine into the area around their affected tooth. The study then measures how well each medication works to numb the area and reduce pain, both during the root canal procedure and afterwards. By comparing the effectiveness of these two treatments, the study seeks to identify which option provides better anesthetic results and pain management for people undergoing dental procedures for symptomatic irreversible pulpitis.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.40 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 55 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Inclusion Criteria: * Systemically healthy patient (ASA I or II). * Mandibular Posterior teeth with: Preoperative sharp pain, Absence or slight widening in the periodontal ligament (PDL), Vital response of pulp tissue to cold pulp test. * patients who agree to provide written consent and the patients able to understand the pain scale and attend for recall appointments Exclusion Criteria: 1. Patients allergic to anesthetic solutions \& other NSAIDs. 2. Pregnant or nursing females. 3. Patients having significant systemic disorder (ASA III or IV). 4. Gastrointestinal disorders. 5. If the initial diagnosis revealed pain in more than one tooth. 6. Hemostatic disorders or anti-coagulant therapy during the last month. 7. Consumption of opioid or non-opioid analgesics or NSAIDs during the last 12 hours before treatment. 8. Teeth that have: i. Periodontal involvement (with pocket depth greater than 5mm, associated with swelling or fistulous tract, or greater than grade I mobility). ii. No possible restorability. iii.Signs of pulpal necrosis; associated sinus tract or swelling. \-
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Active ComparatorGroup II
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives